Takeda and IDT Biologika Partner to Produce J&J Vaccine

Takeda Pharmaceutical has reached a mutual agreement with German contract manufacturer IDT Biologika to produce doses of Johnson & Johnson’s COVID-19 vaccine.

Under the agreement, Takeda will release some capacity previously reserved at IDT Biologika for manufacturing its dengue vaccine candidate, allowing the contract manufacturer to produce J&J’s single-dose vaccine for three months before reverting to dengue vaccine production.

Tokyo-based Takeda has taken on significant COVID-19 vaccine obligations during the pandemic to help supply Japan, including the production of more than 250 million doses of the Novavax vaccine and the importation and distribution of 50 million Moderna vaccine doses.